- ICH GCP
- US Clinical Trials Registry
- Klinisk forsøg NCT07601841
Light Therapy to Improve Sleep in TBI: Sleep-active Biomarkers and Glymphatic Function (GLIMPSE-LION)
18. maj 2026 opdateret af: Jonathan Elliott, Oregon Health and Science University
Light Therapy to Improve Sleep in Veterans With TBI: Sleep-active Biomarkers and Glymphatic Function
This is a clinical trial designed to examine how improved sleep through morning bright light therapy is improving downstream key physiologic processes related to brain health, i.e., mitochondrial function, systemic inflammation, and glymphatic function.
All proposed methodology is already approved in other IRB applications.
Studieoversigt
Status
Rekruttering
Betingelser
Intervention / Behandling
Undersøgelsestype
Interventionel
Tilmelding (Anslået)
300
Fase
- Ikke anvendelig
Kontakter og lokationer
Dette afsnit indeholder kontaktoplysninger for dem, der udfører undersøgelsen, og oplysninger om, hvor denne undersøgelse udføres.
Studiekontakt
- Navn: Jonathan Elliott, PhD
- Telefonnummer: x51986 503-220-8262
- E-mail: elliojon@ohsu.edu
Studiesteder
-
-
Oregon
-
Portland, Oregon, Forenede Stater, 97239
- Rekruttering
- Oregon Health and Science University
-
Kontakt:
- Jonathan Elliott, PhD
- Telefonnummer: x51986 503-220-8262
- E-mail: elliojon@ohsu.edu
-
-
Deltagelseskriterier
Forskere leder efter personer, der passer til en bestemt beskrivelse, kaldet berettigelseskriterier. Nogle eksempler på disse kriterier er en persons generelle helbredstilstand eller tidligere behandlinger.
Berettigelseskriterier
Aldre berettiget til at studere
- Voksen
- Ældre voksen
Tager imod sunde frivillige
Ingen
Beskrivelse
All subjects must:
- Male and female; any race; 18-89 years of age.
- Be English speaking.*
- Be accessible via phone.
- Be non-decisionally impaired. Determined by assessing the subject's ability to verbalize their understanding of the protocol back to us during the informed consent process.
- Not have a history of macular degeneration.
- Not have a history of bipolar disorder.
- Not be currently using a lightbox or a negative ion generator.
- Not be a shift worker.
- Have a documented history of TBI via the Head Trauma Events Characteristics (HTEC) or OHIO conducted in accordance with VA/DoD Clinical Practice Guidelines.88
- Present with self-reported sleep-wake disturbances.
- Remain clinically stable for current pharmacologic treatment related to depression/anxiety, sleep, and pain.
MRI specific compatibility requirements:
- No pacemaker, wires, defribrillator or implanted heart valves
- No history of head surgery requiring aneurysm clips
- No history of other orthopedic or general surgery requiring the implantation of ferrous pins, joints, electric devices/pumps, or other foreign metal objects
- History of eye exposure to metal (unprotected welding/metalworking/shrapnel) is allowable provided the participant screens negative for metal in the eyes on an orbital x-ray or is able to provide clinical documentation of having screened negative.
- No history of non-removable hearing aids, middle/inner ear prosthesis, or dentures
- No history of claustrophobia; if unsure participant will be pre-screened in our mock scanner
- Not currently pregnant, breastfeeding, or have an implanted IUD. Participants who are unsure of their pregnancy status will be administered an hCG urine pregnancy test the day of their scan.
- Able to lay flat on their back comfortably without a thick pillow for an extended period of time.
Shoulder width does not exceed width for safety fitting in the MRI bore.
- This study is limited to English-speaking participants because all assessments, interventions, and consent materials are currently validated and approved only in English. Expanding to other languages would require translation and psychometric validation, which are beyond the scope and budget of this study. This limitation is acknowledged and will be addressed in future research as resources permit. Finally, the study team is only fluent in English, making it infeasible to accurately consent or interact with non-English speakers without interpreting services which again is outside of the scope of this projects budget and timeline. Proceeding without formal translation services would risk miscommunication in informed consent, data collection, or participant support and thus protects participants informed consent and participant understanding.
Studieplan
Dette afsnit indeholder detaljer om studieplanen, herunder hvordan undersøgelsen er designet, og hvad undersøgelsen måler.
Hvordan er undersøgelsen tilrettelagt?
Design detaljer
- Primært formål: Behandling
- Tildeling: Randomiseret
- Interventionel model: Parallel tildeling
- Maskning: Enkelt
Våben og indgreb
Deltagergruppe / Arm |
Intervention / Behandling |
|---|---|
|
Eksperimentel: Morning Bright Light Therapy
Exposure to bright light in the morning every day for an hour for 4 weeks.
|
Exposure to bright light shortly after waking.
Andre navne:
|
|
Andet: Negative Ion Generator Therapy
Exposure to negative ions in the morning every day for an hour for 4 weeks.
|
Exposure to negative ions shortly after waking.
|
Hvad måler undersøgelsen?
Primære resultatmål
Resultatmål |
Foranstaltningsbeskrivelse |
Tidsramme |
|---|---|---|
|
Define the profile of blood-based markers of systemic inflammation pre- vs post-MBLT.
Tidsramme: From pre-intervention to end of device use (Approximately 4 weeks).
|
The primary outcome defines the pre- to post-intervention change in inflammatory target expression using NULISA proteomics (reporting proteins as NPQ relative units).
|
From pre-intervention to end of device use (Approximately 4 weeks).
|
|
Define mitochondrial function (oxygen consumption rate via Seahorse) pre- vs. post-MBLT.
Tidsramme: From pre-intervention to end of device use (Approximately 4 weeks).
|
The primary outcome of this aim reflects pre- to post-intervention change in mitochondrial bioenergetics.
Specific metrics include basal oxygen consumption rate, maximal oxygen consumption rate, and spare/reserve capacity (difference between maximal and basal oxygen consumption rate).
|
From pre-intervention to end of device use (Approximately 4 weeks).
|
|
Explore glymphatic function via novel multi-model non-contrast-based MRI pre- vs. post-MBLT.
Tidsramme: From pre-intervention to end of device use (Approximately 4 weeks).
|
The primary outcome defines pre- to post-intervention change in MRI visibler perivascular space burden (PVS number/volume).
|
From pre-intervention to end of device use (Approximately 4 weeks).
|
Samarbejdspartnere og efterforskere
Det er her, du vil finde personer og organisationer, der er involveret i denne undersøgelse.
Datoer for undersøgelser
Disse datoer sporer fremskridtene for indsendelser af undersøgelsesrekord og resumeresultater til ClinicalTrials.gov. Studieregistreringer og rapporterede resultater gennemgås af National Library of Medicine (NLM) for at sikre, at de opfylder specifikke kvalitetskontrolstandarder, før de offentliggøres på den offentlige hjemmeside.
Studer store datoer
Studiestart (Faktiske)
12. december 2025
Primær færdiggørelse (Anslået)
12. december 2028
Studieafslutning (Anslået)
30. september 2030
Datoer for studieregistrering
Først indsendt
28. april 2026
Først indsendt, der opfyldte QC-kriterier
18. maj 2026
Først opslået (Faktiske)
22. maj 2026
Opdateringer af undersøgelsesjournaler
Sidste opdatering sendt (Faktiske)
22. maj 2026
Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier
18. maj 2026
Sidst verificeret
1. maj 2026
Mere information
Begreber relateret til denne undersøgelse
Yderligere relevante MeSH-vilkår
Andre undersøgelses-id-numre
- STUDY00028579
- TP240626 (Andet bevillings-/finansieringsnummer: Defense Health Advisory)
Lægemiddel- og udstyrsoplysninger, undersøgelsesdokumenter
Studerer et amerikansk FDA-reguleret lægemiddelprodukt
Ingen
Studerer et amerikansk FDA-reguleret enhedsprodukt
Ingen
Disse oplysninger blev hentet direkte fra webstedet clinicaltrials.gov uden ændringer. Hvis du har nogen anmodninger om at ændre, fjerne eller opdatere dine undersøgelsesoplysninger, bedes du kontakte register@clinicaltrials.gov. Så snart en ændring er implementeret på clinicaltrials.gov, vil denne også blive opdateret automatisk på vores hjemmeside .